Airoldi M, Bumma C, Bertetto O, Gabriele P, Succo G, Pedani F
Department of Medical Oncology, S. Giovanni Antica Sede Hospital, Turin, Italy.
Bull Cancer. 1998 Oct;85(10):892-4.
Twenty patients (13 males, 7 females, median age 61 years, range 27-74) with recurrent adenocarcinoma-like tumors of major (10 patients) and minor (10 patients) salivary gland origin (13 adenoid cystic carcinoma, 5 adenocarcinoma, 1 malignant mixed tumor, 1 undifferentiated carcinoma) were treated with vinorelbine at the dose of 30 mg/m2 i.v. weekly. Sixteen patients had been previously treated with surgery + radiation, 3 with surgery + radiotherapy + Novantrone and 1 with radiotherapy alone. Nine patients had local recurrence, 2 local relapse + metastasis and 9 metastasis alone. Site of metastases are: lung (7), bone (1), lung + bone (2), lung + bone + lymph-node + skin (1). Overall 174 courses were given (median 9, range 6-19). Responses were: PR in 4 patients (20%) with a median duration of 6 months (3-9), 9 NC (45%) with a median duration of 3.5 months and 7 PD (35%). The median survival time was 10 months for PR/NC patients, 4 months for non-responders. Median overall survival was 7 months. Vinorelbine has a moderate activity in these very advanced cases.
20例复发性腺癌样肿瘤患者（13例男性，7例女性，年龄中位数61岁，范围27 - 74岁），肿瘤起源于大唾液腺（10例）和小唾液腺（10例）（13例腺样囊性癌，5例腺癌，1例恶性混合瘤，1例未分化癌），接受长春瑞滨治疗，静脉注射剂量为30mg/m²，每周一次。16例患者先前接受过手术 + 放疗，3例接受过手术 + 放疗 + 诺维本，1例仅接受过放疗。9例患者有局部复发，2例局部复发 + 转移，9例仅有转移。转移部位为：肺（7例）、骨（1例）、肺 + 骨（2例）、肺 + 骨 + 淋巴结 + 皮肤（1例）。共给予174个疗程（中位数9个，范围6 - 19个）。疗效为：4例患者（20%）达到部分缓解（PR），缓解持续时间中位数为6个月（3 - 9个月），9例疾病稳定（NC）（45%），持续时间中位数为3.5个月，7例疾病进展（PD）（35%）。PR/NC患者的中位生存时间为10个月，无反应者为4个月。总中位生存期为7个月。长春瑞滨在这些非常晚期的病例中具有中等活性。
